Gabrielle_20
2022-01-21
🥴
UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading<blockquote>瑞银将BioNTech目标价下调43%，称大流行贸易溢价正在消退</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":630887677,"tweetId":"630887677","gmtCreate":1642775889577,"gmtModify":1642775889738,"author":{"id":3569531614182731,"idStr":"3569531614182731","authorId":3569531614182731,"authorIdStr":"3569531614182731","name":"Gabrielle_20","avatar":"https://static.tigerbbs.com/3687c03e4fcd937f9b3fa40fa7705b14","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>🥴</p></body></html>","htmlText":"<html><head></head><body><p>🥴</p></body></html>","text":"🥴","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/630887677","repostId":1125663172,"repostType":4,"repost":{"id":"1125663172","kind":"news","pubTimestamp":1642774815,"share":"https://www.laohu8.com/m/news/1125663172?lang=zh_CN&edition=full","pubTime":"2022-01-21 22:20","market":"us","language":"en","title":"UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading<blockquote>瑞银将BioNTech目标价下调43%，称大流行贸易溢价正在消退</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125663172","media":"Seeking Alpha","summary":"While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from","content":"<p><html><head></head><body>While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday's close).</p><p><blockquote><html><head></head><body>瑞银仍将BioNTech（纳斯达克：BNTX）维持中性评级，但将其目标价从300美元下调至170美元（较昨日收盘价上涨约9%）。</body></html></blockquote></p><p>Analyst Eliana Merle said that with BioNTech shares down ~40% year to date, "we think the recent move hints at a return to fundamentals after a highly volatile '21."</p><p><blockquote>分析师Eliana Merle表示，BioNTech股价今年迄今已下跌约40%，“我们认为最近的走势暗示在经历了高度波动的21年之后将回归基本面。”</blockquote></p><p>Another big question for the company is what COVID-19 will be like once it becomes endemic and how that will impact the market for vaccine boosters, she notes.</p><p><blockquote>她指出，该公司面临的另一个大问题是，一旦COVID-19成为地方病，它会是什么样子，以及这将如何影响疫苗加强剂市场。</blockquote></p><p>"Key swing factors include: the durability of long-term immunity, novel variants, severity of reinfection, competitor COVID-19 vaccines and long-term pricing," Merle writes. "We think the move to omicron specific vaccines is likely and will drive demand, though questions on whether further boosters beyond an omicron booster may follow," Merle writes.</p><p><blockquote>Merle写道：“关键的摇摆因素包括：长期免疫力的持久性、新变种、再感染的严重程度、竞争对手的COVID-19疫苗和长期定价。”梅尔写道：“我们认为转向奥密克戎特定疫苗是可能的，并且将推动需求，尽管除了奥密克戎加强剂之外，是否会出现进一步的加强剂的问题。”</blockquote></p><p>She notes that the company's pipeline is also too early "to move the needle for shares in '22."</p><p><blockquote>她指出，该公司的管道“在22年推动股价上涨”还为时过早。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading<blockquote>瑞银将BioNTech目标价下调43%，称大流行贸易溢价正在消退</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS cuts BioNTech price target by 43% saying pandemic trade premium is fading<blockquote>瑞银将BioNTech目标价下调43%，称大流行贸易溢价正在消退</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2022-01-21 22:20</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday's close).</p><p><blockquote><html><head></head><body>瑞银仍将BioNTech（纳斯达克：BNTX）维持中性评级，但将其目标价从300美元下调至170美元（较昨日收盘价上涨约9%）。</body></html></blockquote></p><p>Analyst Eliana Merle said that with BioNTech shares down ~40% year to date, "we think the recent move hints at a return to fundamentals after a highly volatile '21."</p><p><blockquote>分析师Eliana Merle表示，BioNTech股价今年迄今已下跌约40%，“我们认为最近的走势暗示在经历了高度波动的21年之后将回归基本面。”</blockquote></p><p>Another big question for the company is what COVID-19 will be like once it becomes endemic and how that will impact the market for vaccine boosters, she notes.</p><p><blockquote>她指出，该公司面临的另一个大问题是，一旦COVID-19成为地方病，它会是什么样子，以及这将如何影响疫苗加强剂市场。</blockquote></p><p>"Key swing factors include: the durability of long-term immunity, novel variants, severity of reinfection, competitor COVID-19 vaccines and long-term pricing," Merle writes. "We think the move to omicron specific vaccines is likely and will drive demand, though questions on whether further boosters beyond an omicron booster may follow," Merle writes.</p><p><blockquote>Merle写道：“关键的摇摆因素包括：长期免疫力的持久性、新变种、再感染的严重程度、竞争对手的COVID-19疫苗和长期定价。”梅尔写道：“我们认为转向奥密克戎特定疫苗是可能的，并且将推动需求，尽管除了奥密克戎加强剂之外，是否会出现进一步的加强剂的问题。”</blockquote></p><p>She notes that the company's pipeline is also too early "to move the needle for shares in '22."</p><p><blockquote>她指出，该公司的管道“在22年推动股价上涨”还为时过早。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3790287-ubs-cuts-biontech-price-target-by-43-saying-pandemic-trade-premium-is-fading\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3790287-ubs-cuts-biontech-price-target-by-43-saying-pandemic-trade-premium-is-fading","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125663172","content_text":"While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday's close).Analyst Eliana Merle said that with BioNTech shares down ~40% year to date, \"we think the recent move hints at a return to fundamentals after a highly volatile '21.\"Another big question for the company is what COVID-19 will be like once it becomes endemic and how that will impact the market for vaccine boosters, she notes.\"Key swing factors include: the durability of long-term immunity, novel variants, severity of reinfection, competitor COVID-19 vaccines and long-term pricing,\" Merle writes. \"We think the move to omicron specific vaccines is likely and will drive demand, though questions on whether further boosters beyond an omicron booster may follow,\" Merle writes.She notes that the company's pipeline is also too early \"to move the needle for shares in '22.\"","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2469,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/630887677"}
精彩评论